Publicacions en què col·labora amb DANIEL ERNESTO CASTELLANO GAUNA (10)

2023

  1. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

    European Journal of Cancer, Vol. 188, pp. 39-48

2019

  1. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

    Oncologist, Vol. 24, Núm. 1, pp. 38-46

2018

  1. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

2017

  1. Translational research in neuroendocrine tumors: Pitfalls and opportunities

    Oncogene, Vol. 36, Núm. 14, pp. 1899-1907

2016

  1. Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case

    Case Reports in Oncology, Vol. 9, Núm. 1, pp. 255-261

2015

  1. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993

2013

  1. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. the large experience of the spanish national tumor registry (RGETNE)

    Neuroendocrinology, Vol. 98, Núm. 2, pp. 156-168

  2. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787

2011

  1. Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

    Cancer and Metastasis Reviews, Vol. 30, Núm. SUPPL. 1

2010

  1. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)

    Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803